DOCSLIB.ORG

Acrivastine/Astemizole 567

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acrivastine/Astemizole 567 Acrivastine/Astemizole 567 Antazoline (BAN, rINN) It is used as the hydrochloride, phosphate, or sulfate in eye drops, evaluation including ECG monitoring instituted, because synco- most commonly in a concentration of 0.5%; the mesilate has also pe has preceded or accompanied severe arrhythmias in some cas- Antatsoliini; Antazolin; Antazolina; Antazolinum. N-Benzyl-N-(2- been used. Antazoline salts are often used with a vasoconstrictor es. Convulsions in patients taking astemizole may also be related imidazolin-2-ylmethyl)aniline. such as naphazoline hydrochloride or nitrate or xylometazoline to cardiovascular effects.8 Антазолин hydrochloride. Studies have suggested that astemizole induces ventricular ar- C17H19N3 = 265.4. The hydrochloride and sulfate salts of antazoline have been used rhythmias by inhibiting cardiac potassium channels which re- CAS — 91-75-8. topically for the treatment of minor skin irritations, but as with sults in prolongation of the QT interval, a risk factor for develop- ATC — R01AC04; R06AX05. other antihistamines there is a risk of sensitisation. The hydro- ing arrhythmias.9 For further discussion, see p.562. ATC Vet — QR01AC04; QR06AX05. chloride has also been given by mouth. 1. Simons FER, et al. Astemizole-induced torsade de pointes. Lan- cet 1988; ii: 624. Preparations 2. Hoppu K, et al. Accidental astemizole overdose in young chil- Proprietary Preparations (details are given in Part 3) dren. Lancet 1991; 338: 538–40. 3. Tobin JR, et al. Astemizole-induced cardiac conduction distur- H Multi-ingredient: Austral.: Albalon-A; Antistine-Privine; In A Wink Al- bances in a child. JAMA 1991; 266: 2737–40. N lergy†; Austria: Histophtal; Belg.: Zincfrin Antihistaminicum†; Canad.: Al- 4. Wiley JF, et al. Cardiotoxic effects of astemizole overdose in N balon-A; Vasocon-A†; Zincfrin-A; Chile: Albasol A†; Bacitopic Compuesto; Nasomin; Oftalirio; Red Off Plus; Rinobanedif; Spersallerg; Cz.: Sanorin- children. J Pediatr 1992; 120: 799–802. N Analergin; Spersallerg; Denm.: Ansal; Antistina-Privin; Sesal; Fin.: Antistin- 5. CSM. Ventricular arrhythmias due to terfenadine and astemizole. Privin†; Zincfrin-A†; Ger.: Allergopos N; Antistin-Privin; Spersallerg; Gr.: Current Problems 35 1992. Also available at: Spersallerg; Hong Kong: Spersallerg; Hung.: Spersallerg; Indon.: Indofrin- http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE& A; Irl.: Otrivine-Antistin; RBC; Israel: Antistin-Privin†; Ital.: Antistin-Privina; dDocName=CON2024453&RevisionSelectionMethod= Malaysia: Alergoftal; Napha A; Spersallerg; Mex.: Midazol Ofteno; Ofta- LatestReleased (accessed 14/07/08) lirio†; Zincfrin-A; Norw.: Spersallerg; NZ: Albalon-A†; Otrivine-Antistin; 6. CSM/MCA. Drug-induced prolongation of the QT interval. Cur- Philipp.: Spersallerg; Pol.: Dermophenazol; Oftophenazol; Rhinophena- rent Problems 1996; 22: 2. Also available at: Antazoline Hydrochloride (BANM, rINNM) zol; Spersallerg; Port.: Alergiftalmina; Rus.: Sanorin-Analergin (Санорин- http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE& аналергин); Spersallerg (Сперсаллерг); S.Afr.: Albalon-A†; Antistin-Privin; Antatsoliinihydrokloridi; Antazolin hydrochlorid; Antazoline, dDocName=CON2024458&RevisionSelectionMethod= Covosan; Gemini; Oculerge; Safyr Bleu Antihistamine†; Spersallerg; Zinc- LatestReleased (accessed 14/07/08) chlorhydrate d’; Antazolin-hidroklorid; Antazolinhydroklorid; An- frin-A; Singapore: Antistin-Privin; Spersallerg; Spain: Alergoftal; Swed.: 7. CSM/MCA. Astemizole (Hismanal): only available on prescrip- tazolini Hydrochloricum; Antazolini hydrochloridum; Antazolin- Antasten-Privin; Switz.: Antistin-Privin; Spersallerg; Thai.: Antazallerge; Histaoph; Opsa-His†; Opsil-A; Spersallerg; Turk.: Alergoftal; Sulfarhin; UK: tion. Current Problems 1999; 25: 2. Also available at: ium Chloride; Antazolino hidrochloridas; Antazoliny chlorowo- Otrivine-Antistin; USA: Antazoline-V; Vasocon-A. http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE& dorek; Hidrocloruro de antazolina; Imidamine Hydrochloride; dDocName=CON2023233&RevisionSelectionMethod= Phenazolinum. LatestReleased (accessed 19/05/06) 8. Clark A, Love H. Astemizole-induced ventricular arrhythmias: Антазолина Гидрохлорид an unexpected cause of convulsions. Int J Cardiol 1991; 33: Astemizole (BAN, USAN, rINN) C17H19N3,HCl = 301.8. 165–7. CAS — 2508-72-7. Astemitsoli; Astemizol; Astemizolas; Astémizole; Astemizolum; 9. Rankin AC. Non-sedating antihistamines and cardiac arrhyth- mia. Lancet 1997; 350: 1115–16. ATC — R01AC04; R06AX05. Asztemizol; MJD-30. 1-(4-Fluorobenzyl)-2-{[1-(4-methoxy- ATC Vet — QR01AC04; QR06AX05. phenethyl)-4-piperidyl]amino}benzimidazole. Overdosage. Severe cardiac events have been associated with Pharmacopoeias. In Chin. and Eur. (see p.vii). astemizole overdosage (see Arrhythmias, above); management Ph. Eur. 6.2 (Antazoline Hydrochloride). A white or almost Астемизол is mainly supportive. The absorption of astemizole from the gas- 1 white crystalline powder. Sparingly soluble in water; soluble in C28H31FN4O = 458.6. trointestinal tract can be prevented by giving activated charcoal alcohol; slightly soluble in dichloromethane. CAS — 68844-77-9. but because astemizole is rapidly absorbed it would need to be given as soon as possible after poisoning. Haemodialysis does ATC — R06AX11. not appear to increase the clearance of astemizole. Antazoline Mesilate (BANM, rINNM) ATC Vet — QR06AX11. 1. Laine K, et al. The effect of activated charcoal on the absorption Antazoline, Mésilate d’; Antazoline Mesylate; Antazoline Meth- and elimination of astemizole. Hum Exp Toxicol 1994; 13: anesulphonate; Antazolini Mesilas; Antazoliny mezylan; Imidam- 502–5. ine Mesylate; Mesilato de antazolina. F Porphyria. Astemizole is considered to be unsafe in patients Антазолина Мезилат with porphyria because it has been shown to be porphyrinogenic C H N ,CH SO H = 361.5. 17 19 3 3 3 OCH in in-vitro systems. CAS — 3131-32-6. N 3 N N Sedation. For discussion of the sedative effects of antihista- ATC — R01AC04; R06AX05. H ATC Vet — QR01AC04; QR06AX05. N mines see p.562. Pharmacopoeias. In Pol. Interactions NOTE. The code R-43512 has been used to describe both astemi- As for the non-sedating antihistamines in general, p.563. zole and its metabolite tecastemizole (norastemizole). Antazoline Phosphate (BANM, rINNM) Astemizole should not be given with drugs that inhibit its hepatic Antazolin Fosfat; Antazoline, Phosphate d’; Antazolini Phosphas; Pharmacopoeias. In Eur. (see p.vii) and US. metabolism because of the increased risk of serious ventricular arrhythmias. These drugs include the imidazole and triazole an- Fosfato de antazolina; Imidamine Phosphate. Ph. Eur. 6.2 (Astemizole). A white or almost white powder. Practically insoluble in water; soluble in alcohol; freely soluble tifungals such as ketoconazole and itraconazole, and the mac- Антазолина Фосфат in dichloromethane and in methyl alcohol. Protect from light. rolide antibacterials clarithromycin, erythromycin, troleandomy- C17H19N3,H3PO4 = 363.3. USP 31 (Astemizole). Store in airtight containers. cin, and possibly other macrolides. Others, similarly to CAS — 154-68-7. terfenadine (p.591), may include serotonin reuptake inhibitors, ATC — R01AC04; R06AX05. Adverse Effects and Precautions HIV-protease inhibitors, NNRTIs, and zileuton. The metabolism ATC Vet — QR01AC04; QR06AX05. As for the non-sedating antihistamines in general, p.561. In- of astemizole may also be inhibited by grapefruit juice and use Pharmacopoeias. In US. creased appetite and weight gain have been reported with astem- together should be avoided. USP 31 (Antazoline Phosphate). A white to off-white crystalline izole. Use with other potentially arrhythmogenic drugs (including powder. Soluble in water; practically insoluble in ether and in Ventricular arrhythmias, including torsade de pointes, have oc- those that prolong the QT interval) such as antiarrhythmics, tri- benzene; sparingly soluble in methyl alcohol. pH of a 2% solu- curred rarely with astemizole, particularly in association with cyclic antidepressants, the antimalarials halofantrine and qui- tion in water is between 4.0 and 5.0. Store in airtight containers. raised blood concentrations (see Arrhythmias below) and as a re- nine, antipsychotics, cisapride, and the beta blocker sotalol sult the drug has been withdrawn from the market in most coun- should be avoided, as should diuretics that cause electrolyte im- balances such as hypokalaemia. The use of terfenadine and Antazoline Sulfate (rINNM) tries. To reduce the risk of developing such arrhythmias recom- mendations were that licensed doses should not be exceeded, astemizole together is not recommended. Antazoline, Sulfate d’; Antazoline Sulphate (BANM); Antazolini Sul- and that it should be avoided in patients with cardiac or signifi- fas; Imidamine Sulphate; Sulfato de antazolina. cant hepatic disease, with hypokalaemia or other electrolyte im- Pharmacokinetics Absorption of astemizole from the gastrointestinal tract is rapid Антазолина Сульфат balance, or with known or suspected prolonged QT interval. Use with drugs liable to interfere with the hepatic metabolism of and is reduced by food. First-pass metabolism is extensive, there- (C17H19N3)2H2SO4,2H2O = 664.8. astemizole, other potentially arrhythmogenic drugs including fore plasma concentrations of unchanged drug are very low. The CAS — 24359-81-7 (anhydrous antazoline sulfate). plasma concentration of astemizole plus metabolites takes about ATC — R01AC04; R06AX05. those that prolong the QT interval, and drugs likely
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • HMSA Drug Formulary
    March 23, 2004 MEMORANDUM TO: Participating Pharmacies FROM: John T. Berthiaume, M.D. Medical Director, Pharmacy Management SUBJECT: Updated HMSA Drug Formulary Enclosed is the comprehensive updated formulary, effective April 1. This copy incorporates the changes listed in the Formulary Update sent to you in February. Please replace the current formulary sections in your pharmacy handbook with the enclosed version. If you have any questions, please call an HMSA Provider Teleservice Representative at 948- 6330 on Oahu or 1 (800) 790-4672 from the Neighbor Islands. PM04-010 HMSA DRUG FORMULARY 4/1/04 - Page 1 Code THERAPEUTIC CATEGORY LISTING 1 I. Anti-infectives A. Antibiotics 1. Penicillins - non-penicillinase resistant 2 I. Anti-infectives A. Antibiotics 2. Penicillins - penicillinase resistant 3 I. Anti-infectives A. Antibiotics 3. Cephalosporins 4 I. Anti-infectives A. Antibiotics 4. Fluoroquinolones 5 I. Anti-infectives A. Antibiotics 5. Tetracyclines 6 I. Anti-infectives A. Antibiotics 6. Macrolides 7 I. Anti-infectives A. Antibiotics 7. Vancomycin 8 I. Anti-infectives A. Antibiotics 8. Lincosamides 9 I. Anti-infectives A. Antibiotics 9. Aminoglycoside 10 I. Anti-infectives A. Antibiotics 10. Sulfonamides 11 I. Anti-Infectives A. Antibiotics 11. Vaginal preparations 12 I. Anti-infectives B. Antifungal agents 1. Oral 13 I. Anti-Infectives B. Antifungal agents 2. Vaginal preparations OTC considerations: clotrimazole (Gyne-Lotrimin 3, Mycelex-7), miconazole (Monistat 7), tioconazole (Vagistat-1), butoconazole (Femstat 3) 14 I. Anti-infectives C. Antimalarial 15 I. Anti-infectives D. Antituberculous 16 I. Anti-infectives E. Amebicides 17 I. Anti-infectives F. Antiviral agents 1. Nucleoside Reverse-transcriptase Inhibitors (NRTI) 18 I.
    [Show full text]
  • Inhibition of Histamine-Induced Human Conjunctival Epithelial Cell Responses by Ocular Allergy Drugs
    LABORATORY SCIENCES Inhibition of Histamine-Induced Human Conjunctival Epithelial Cell Responses by Ocular Allergy Drugs John M. Yanni, PhD; Lori K. Weimer, BA; Najam A. Sharif, PhD; Shou X. Xu, MS; Daniel A. Gamache, PhD; Joan M. Spellman, MS Objective: To evaluate the effects of topical ocular drugs secretion (50% inhibitory concentration, 1.7-5.5 nmol/L) with histamine H1-antagonist activity on histamine- than predicted from binding data, while antazoline and stimulated phosphatidylinositol turnover and interleu- pheniramine were far less potent (20- to 140-fold) in func- kin (IL) 6 and IL-8 secretion from human conjunctival tional assays. Levocabastine (dissociation constant, 52.6 epithelial cells. nmol/L) exhibited greater functional activity (50% in- hibitory concentration, 8-25 nmol/L) than either antazo- Methods: Primary human conjunctival epithelial cell cul- line or pheniramine. tures were stimulated with histamine in the presence or ab- sence of test drugs. Phosphatidylinositol turnover was quan- Conclusions: Histamine-stimulated phosphatidylino- tified by ion exchange chromatography and cytokine con- sitol turnover and cytokine secretion by human conjunc- tentofsupernatantsbyenzyme-linkedimmunosorbentassay. tival epithelial cells are attenuated by compounds with H1-antagonist activity. However, antihistaminic po- Results: Antazoline hydrochloride, emedastine difuma- tency alone does not predict anti-inflammatory poten- rate, levocabastine hydrochloride, olopatadine hydro- tial. Olopatadine, emedastine, and levocabastine were no- chloride, and pheniramine maleate attenuated histamine- tably more potent than pheniramine and antazoline. stimulated phosphatidylinositol turnover and IL-6 and IL-8 secretion. Emedastine was the most potent in li- Clinical Relevance: Selected topical ocular drugs with gand binding, phosphatidylinositol turnover, and IL-6 se- antihistaminic activity may offer therapeutic advan- cretion, with dissociation constant and 50% inhibitory tages to patients with allergic conjunctivitis by inhibit- concentrations of 1-3 nmol/L.
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Determination of Antidepressants in Human Plasma by Modified Cloud
    pharmaceuticals Article Determination of Antidepressants in Human Plasma by Modified Cloud-Point Extraction Coupled with Mass Spectrometry El˙zbietaGniazdowska 1,2 , Natalia Korytowska 3 , Grzegorz Kłudka 3 and Joanna Giebułtowicz 3,* 1 Łukasiewicz Research Network, Industrial Chemistry Institute, 8 Rydygiera, 01-793 Warsaw, Poland; [email protected] 2 Department of Bioanalysis and Drugs Analysis, Doctoral School, Medical University of Warsaw, 61 Zwirki˙ i Wigury, 02-091 Warsaw, Poland 3 Department of Bioanalysis and Drugs Analysis, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha, 02-097 Warsaw, Poland; [email protected] (N.K.); [email protected] (G.K.) * Correspondence: [email protected] Received: 5 October 2020; Accepted: 7 December 2020; Published: 12 December 2020 Abstract: Cloud-point extraction (CPE) is rarely combined with liquid chromatography coupled to mass spectrometry (LC–MS) in drug determination due to the matrix effect (ME). However, we have recently shown that ME is not a limiting factor in CPE. Low extraction efficiency may be improved by salt addition, but none of the salts used in CPE are suitable for LC–MS. It is the first time that the influences of a volatile salt—ammonium acetate (AA)—on the CPE extraction efficiency and ME have been studied. Our modification of CPE included also the use of ethanol instead of acetonitrile to reduce the sample viscosity and make the method more environmentally friendly. We developed and validated CPE–LC–MS for the simultaneous determination of 21 antidepressants in plasma that can be useful for clinical and forensic toxicology. The selected parameters included Triton X-114 concentration (1.5 and 6%, w/v), concentration of AA (0, 10, 20 and 30%, w/v), and pH (3.5, 6.8 and 10.2).
    [Show full text]
  • Otrivine-Antistin-Uk-Spc-09Jan19.Pdf
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Otrivine Antistin Eye Drops Xylometazoline 0.05% w/v Antazoline 0.5% w/v 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Xylometazoline hydrochloride 0.05% Antazoline sulphate 0.5% For excipients see Section 6.1. 3. PHARMACEUTICAL FORM Eye drops solution A clear colourless solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications For the temporary relief of redness and itching of the eye due to seasonal and perennial allergies such as hay fever or house dust allergy. 4.2 Posology and method of administration For local administration to the eye. Adults: 1 or 2 drops instilled 2 - 3 times a day. Children: No specific studies are available in this patient group. Due to possible systemic effects, Otrivine-Antistin is not recommended for use in children younger than 12 years of age. Elderly: One drop instilled 2 to 3 times a day. Otrivine Antistin Eye Drops should not be used for more than seven consecutive days. The dispenser remains sterile until the original closure is broken. Patients must be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures as this may contaminate the solution. If more than one medication needs to be instilled in the eye, an interval of at least 5 minutes between application of the different medicinal products must be allowed. 4.3 Contraindications Hypersensitivity to any of the ingredients of the formulation Presence of narrow angle glaucoma Use with contact lenses Use in patients receiving monoamine oxidase inhibitors or within 14 days of stopping such treatment (See section 4.5) 4.4 Special warnings and precautions for use Like other topically applied ophthalmic drugs, Otrivine-Antistin may be absorbed systemically and occasionally cause systemic sympathomimetic effects such as hypertension, nervousness, nausea, dizziness, headache, insomnia, palpitation, tachycardia, and arrhythmia.
    [Show full text]
  • NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Drug
    Quantitative Safety & Epidemiology NVA237 / Glycopyrronium bromide Non-interventional Final Study Report NVA237A2401T Multinational, multi-database drug utilization study of inhaled NVA237 in Europe Author Document Status Final Date of final version 28 April 2016 of the study report EU PAS register ENCEPP/SDPP/4845 number Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis NIS Report Template Version 2.0 August-13-2014 Novartis Confidential Page 2 Non-interventional study report NVA237A/Seebri® Breezhaler®/CNVA237A2401T PASS information Title Multinational, multi-database drug utilization study of inhaled NVA237 in Europe –Final Study Report Version identifier of the Version 1.0 final study report Date of last version of 28 April 2016 the final study report EU PAS register number ENCEPP/SDPP/4845 Active substance Glycopyrronium bromide (R03BB06) Medicinal product Seebri®Breezhaler® / Tovanor®Breezhaler® / Enurev®Breezhaler® Product reference NVA237 Procedure number SeebriBreezhaler: EMEA/H/C/0002430 TovanorBreezhaler: EMEA/H/C/0002690 EnurevBreezhaler: EMEA/H/C0002691 Marketing authorization Novartis Europharm Ltd holder Frimley Business Park Camberley GU16 7SR United Kingdom Joint PASS No Research question and In the context of the NVA237 marketing authorization objectives application, the Committee for Medicinal Products for Human Use (CHMP) recommended conditions for marketing authorization and product information and suggested to conduct a post-authorization
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Comparative Study of 0.1% Olopatadine Hydrochloride and 0.5% Ketorolac Tromethamine in the Treatment of Seasonal Allergic Conjunctivitis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE ACTA OPHTHALMOLOGICA SCANDINAVICA 2003 Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis Volkan Yaylali, Ibrahim Demirlenk, Sinan Tatlipinar, Davut O¨zbay, Arif Esme, Cem Yildirim and Serap O¨zden Pamukkale University School of Medicine, Department of Ophthalmology, Denizli, Turkey ABSTRACT. Purpose: To compare the therapeutic effects of two ophthalmic solutions (0.1% Introduction olopatadine hydrochloride and 0.5% ketorolac tromethamine) with different Seasonal allergic conjunctivitis (SAC) pharmacological mechanisms on the clinical signs and Symptoms of seasonal or hay fever is a common allergic dis- allergic conjunctivitis (SAC). ease typically elicited by airborne aller- Methods: Forty patients with the signs and symptoms of SAC (i.e. hyperaemia, gens such as pollen, grass, weeds and itching, mucus discharge, tearing) were included in this placebo-controlled, ran- animal dander (Abelson & Schaefer domized, parallel group, single centre study. In group 1 (20 patients) one eye of 1993). It is a type 1 hypersensitivity each patient was treated with olopatadine and the other with placebo. In group 2 reaction mediated by IgE in response (20 patients) one eye of each patient was treated with ketorolac solution and the to these environmental antigens. The other with placebo. The principal signs and symptoms of SAC (hyperaemia and principal symptom of SAC is ocular itching) were evaluated at 30 mins and at 2, 7 and 15 days. itching (Abelson & Schaefer 1993). Results: In group 1, both parameters improved significantly in eyes treated with Other signs and symptoms include con- olopatadine compared with those receiving placebo at all control examinations junctival hyperaemia, tearing, mucus (all p < 0.05).
    [Show full text]